Clarimedix Gets Backing From Johnson & Johnson

Boulder-based Clarimedix, a developer of non-invasive therapeutics for treating vascular dysfunction, has scored an investment from the Johnson & Johnson Corporate Office of Science and Technology (COSAT). Financial details of the investment round were not announced by the firm. Clarimedix said it will use the new funding for a human proof-of-concept study on its product. The firm explained that it expects to seek further funding after the completion of that study by the end of Q2. Clarimedix is headed by John Dunning, who was formerly at Wasatch Venture Fund (now Epic Ventures). The firm's scientific founder is Dr. Robert Poynton, who is at the University of Colorado, Boulder. More information »